Selective inhibition of collagen accumulation by N-(3, 4-dimethoxycinnamoyl)anthranilic acid (N-5') in granulation tissue

doi:10.1016/0006-2952(87)90353-4

Biochemical Pharmacology

Volume 36, Issue 4, 15 February 1987, Pages 469-474

https://doi.org/10.1016/0006-2952(87)90353-4 Get rights and content

Abstract

The effect of topically applied N-5', an inhibitor of chemical mediator release from mast cells, on the carrageenin-air-pouch inflammation was studied. The formation of granulation tissue, the accumulation of exudate and the number of infiltrating cells were significantly reduced by the treatment with N-5' (100 mg/kg).

The collagen content in granulation tissue was dose-dependently reduced without affecting the noncollagen protein and DNA content by treatment with N-5'. At a dose of 100 mg/kg of N-5', prolyl hydroxylase activity in the tissue was significantly decreased. The selective inhibition of collagen accumulation in granulation tissue resulted from reduction of collagen biosynthesis in vivo.

N-5' did not directly inhibit collagen synthesis by diploid fibroblasts, but inhibited fibroblast proliferation in culture. Such results indicate that one of the inhibitory mechanisms of collagen accumulation by N-5' in inflamed sites may involve the inhibition of fibroblast proliferation.

References (25)

J.M. Seyer
Fundam. appl. Toxicol.
(1976)
O.H. Lowry et al.
J. biol. Chem.
(1951)
K.W. Giles et al.
Nature, Lond.
(1965)
B. Peterkofsky et al.
Biochemistry
(1971)
J. Uitto et al.
J. Invest. Dermat.
(1979)
D.J. Prockop et al.
New Eng. J. Med.
(1979)
D.J. Prockop et al.
New Eng. J. Med.
(1979)
R. Pérez-Tamayo
Am. J. Pathol.
(1978)
A. Hatamochi et al.
Arch. Dermatol. Res.
(1985)
J.R. Boucek
Otolaryng, Clin, North America.
(1984)
T.L. Whiteside et al.
J. Lab. clin. Med.
(1984)

P.H. Hart et al.

Scand. J. Immunol.

(1983)

R.L. Johnson et al.

J. clin. Invest.

(1976)

Cited by (76)

Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review
2021, Food and Chemical Toxicology
Citation Excerpt :
It is a potent inhibitor of NLRP3 which is an inflammasome that drives inflammation in many disorders including bronchial asthma (Huang et al., 2018) (Fig. 1B). Tranilast represses fibrosis by inhibition of fibroblast activity (Isaji et al., 1987) and collagen formation via reducing the activity of TGF-β (Suzawa et al., 1992). It has been proved that it mitigates the pulmonary fibrosis in experimental animals (Mori et al., 1995).
Coronavirus disease-19 (COVID-19) is a complex disease that causes illness ranging from mild to severe respiratory problems. It is caused by a novel coronavirus SARS-CoV-2 (Severe acute respiratory syndrome coronavirus-2) that is an enveloped positive-sense single-stranded RNA (+ssRNA) virus belongs to coronavirus CoV family. It has a fast-spreading potential worldwide, which leads to high mortality regardless of lows death rates. Now some vaccines or a specific drug are approved but not available for every country for disease prevention and/or treatment. Therefore, it is a high demand to identify the known drugs and test them as a possible therapeutic approach. In this critical situation, one or more of these drugs may represent the only option to treat or reduce the severity of the disease, until some specific drugs or vaccines will be developed and/or approved for everyone in this pandemic. In this updated review, the available repurpose immunotherapeutic treatment strategies are highlighted, elucidating the crosstalk between the immune system and SARS-CoV-2. Despite the reasonable data availability, the effectiveness and safety of these drugs against SARS-CoV-2 needs further studies and validations aiming for a better clinical outcome.
Enhanced biopharmaceutical effects of tranilast on experimental colitis model with use of self-micellizing solid dispersion technology
2018, International Journal of Pharmaceutics
The present study aimed to clarify the applicability of a self-micellizing solid dispersion of tranilast (SMSD/TL) to the treatment of inflammatory bowel diseases (IBD) using an experimental colitis model. SMSD/TL with several loading amounts ranging from 10 to 50% was prepared using a wet-milling system. The physicochemical properties of SMSD/TL were evaluated in terms of the dissolution behavior, morphology, and particle size distribution. Animal studies were conducted to evaluate oral bioavailability in rats and anti-inflammatory effects in a rat model of chemically induced colitis. SMSD/TL with drug loading of 15% (SMSD/TL15) showed enhanced dissolution behavior at pH 1.2, compared with other tested other formulations. After the dispersion of SMSD/TL15 in deionized water, fine micelles formed with an average diameter of 137 nm. SMSD/TL15 (10 mg-TL/kg) exhibited about 147- and 34-fold greater value for C_max and the area under the curve of plasma concentration vs. time than crystalline TL, respectively. Although the anti-inflammatory effect on the colitis model was very limited in the crystalline TL (2 mg/kg) group, inflammatory events, such as myeloperoxidase activity and thickening of the submucosa in colon tissues, were significantly suppressed in the SMSD/TL15 (2 mg-TL/kg) group. Based on these findings, SMSD/TL might be a more efficacious dosage option for improved IBD treatment.
TRPV2 channel inhibitors attenuate fibroblast differentiation and contraction mediated by keratinocyte-derived TGF-β1 in an in vitro wound healing model of rats
2018, Journal of Dermatological Science
Citation Excerpt :
Therefore, we considered that TRPV2 may be involved in the contraction of the collagen gel. Tranilast has been used clinically to improve keloid and hypertrophic scars because of its inhibition of collagen accumulation in granulation tissue [26]. Tranilast was shown to inhibit the release of TGF-β1 from keloid fibroblasts, but not from healthy skin fibroblasts, and to suppress collagen synthesis in keloid fibroblasts [27].
Keratinocytes release several factors that are involved in wound contracture and scar formation. We previously reported that a three-dimensional reconstruction model derived from rat skin represents a good wound healing model.
We characterized the role of transient receptor potential (TRP) channels in the release of transforming growth factor (TGF)-β1 from keratinocytes and the differentiation of fibroblasts to identify possible promising pharmacological approaches to prevent scar formation and contractures.
The three-dimensional culture model was made from rat keratinocytes seeded on a collagen gel in which dermal fibroblasts had been embedded.
Among the TRP channel inhibitors tested, the TRPV2 inhibitors SKF96365 and tranilast attenuated most potently keratinocyte-dependent and — independent collagen gel contraction due to TGF-β signaling as well as TGF-β1 release from keratinocytes and α-smooth muscle actin production in myofibroblasts. Besides the low amounts detected in normal dermis, TRPV2 mRNA and protein levels were increased after fibroblasts were embedded in the gel. TRPV2 was also expressed in the epidermis and keratinocyte layers of the model. Both inhibitors and TRPV2 siRNA attenuated the intracellular increase of Ca²⁺ induced by the TRPV agonist 2-aminoethoxydiphenyl borate in TGF-β1-pretreated fibroblasts.
This is the first study to show that compounds targeting TRPV2 channels ameliorate wound contraction through the inhibition of TGF-β1 release and the differentiation of dermal fibroblasts in a culture model.
Determination of tranilast in bio-samples by LC–MS/MS: Application to a pharmacokinetic and brain tissue distribution study in rats
2018, Journal of Pharmaceutical and Biomedical Analysis
Citation Excerpt :
Tranilast (Fig. 1A), [N-(3,4-dimethoxycinnamoyl) anthranilic acid, as an anti-allergic drug used clinically for the treatment of bronchial asthma, atopic dermatitis, allergic conjunctivitis, keloid and hypertrophic scar [1–9], has been subsequently identified as a potent drug for the nervous system disorder [10].
As a potent drug used to improve the neurodegenerative conditions, there is few information about the brain tissue distribution of tranilast by now. In this study, a novel sensitive LC–MS/MS method has been developed and validated to determine tranilast in rat brain tissue samples. The calibration curve showed good linearity ranged from 2.140 to 428.0 ng·mL⁻¹. The method was fully validated and successfully applied in the brain tissue distribution study of tranilast in rats, which had never been reported in detail by now. Furthermore, a rapid LC–MS/MS method with a short run time of 3 min was developed and validated for the determination of tranilast in rat plasma and the application to a pharmacokinetic study of tranilast in rats. After oral dosage of 10.5 mg·kg⁻¹ tranilast, the maximum plasma concentration (C_max¹) of tranilast was (18.59 ± 5.40) μg·mL⁻¹ at (0.667 ± 0.408) h while the area under the curve (AUC_0-24) was (54.87 ± 14.13) μg·h·mL⁻¹ with the elimination half-life of (2.93 ± 0.41) h. The ratio calculated by dividing the concentration of tranilast in brain with the concentration of tranilast in the plasma, was (0.6042% ± 0.0572%), (0.7484% ± 0.0883%), (0.5914% ± 0.0416%) and (0.3830% ± 0.1632%) at 0.167, 0.5, 2 and 8 h, respectively. The results showed that tranilast with fast absorption could penetrate the rat brain blood barrier after oral gavage. The obtained data also showed that tranilast could be quickly distributed and eliminated in brain tissue.
Protective effects of tranilast on experimental colitis in rats
2017, Biomedicine and Pharmacotherapy
Citation Excerpt :
Tranilast (TL), N-(3,4-dimethoxycinnamoyl) anthranilic acid, has been shown to have anti-inflammatory and anti-allergic effects and inhibit the release of inflammatory mediators from mast cells and basophils [9,10]; thus, TL is clinically used for treating bronchial asthma, atopic rhinitis, and atopic dermatitis [11]. Other suppressive effects of TL have also been reported, including collagen synthesis [12], the action of transforming growth factor beta (TGF-β) [13,14], and the production of TNF-α [15], and TL is expected to show therapeutic potential against fibrotic diseases and cancer. According to a case report, the oral administration of TL (300 mg/day) to a female CD patient improved inflammatory symptoms, maintained long-term remission, and prevented the relapse of bowel inflammation [16].
The present study aimed to verify the efficacy of tranilast (TL) for treating inflammatory bowel disease (IBD) with the use of an experimental colitis model. The experimental colitis model was prepared by intrarectal instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS; 40 mg/kg) dissolved in water containing 25% ethanol. The pharmacological effects of TL after repeated oral administration were evaluated by biomarker and histological analyses, and the pharmacokinetic behavior of TL was also examined after single oral administration. The intrarectal instillation of TNBS solution caused colitis, as evidenced by ca. 2.2-, 5-, and 3-fold increases in myeloperoxidase (MPO) activity, infiltrated cell numbers, and the thickness of the submucosa in the colon, respectively. However, orally-taken TL (10 mg/kg, twice a day for 9 days) led to a 92% reduction in the increase of the MPO level by TNBS enema, and cellular infiltration and thickened submucosa in the experimental colitis model tended to also be suppressed by repeated oral administration of TL. The oral bioavailability of TL in TNBS-treated rats was calculated to be as low as ca. 6.5%, and the poor oral absorption of TL may be a limitation of the treatment for IBD. TL could attenuate TNBS-induced colitis on the basis of the obtained results, and the anti-inflammatory effects would have clinical relevance to the therapeutic outcomes of TL in IBD patients. Although further improvement in the oral bioavailability of TL might be required for better pharmacological outcomes, TL would be an efficacious agent for treating IBD.
Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment
2016, Cancer Letters
Angiogenesis is sustained by classical and non-classical proangiogenic factors (PFs) acting in tumor microenvironment and these factors are also potential targets of antiangiogenic therapies. All PFs induce the overexpression of several signaling pathways that lead to migration and proliferation of endothelial cells contributing to tumor angiogenesis and survival of cancer cells. In this review, we have analyzed each PF with its specific receptor/s and we have summarized the available antiangiogenic drugs (e.g. monoclonal antibodies) targeting these PFs, some of these agents have already been approved, others are currently in development for the treatment of several human malignancies.

View all citing articles on Scopus

View full text

Selective inhibition of collagen accumulation by N-(3, 4-dimethoxycinnamoyl)anthranilic acid (N-5') in granulation tissue

Abstract

Fundam. appl. Toxicol.

J. biol. Chem.

Nature, Lond.

Biochemistry

J. Invest. Dermat.

New Eng. J. Med.

New Eng. J. Med.

Am. J. Pathol.

Arch. Dermatol. Res.

Otolaryng, Clin, North America.

J. Lab. clin. Med.

Scand. J. Immunol.

J. clin. Invest.